(Telestock) – Swas Biosanaa company listed on Euronext Growth Milan and active in the production of medical devices for healthcare facilities, has closed the first semester of 2024 with consolidated revenues equal to 58.2 million euros, up 5.8% compared to the same period of the previous financial year (approximately 55 million).
The growth of the is confirmed Business Unit Farmex – production and marketing of incontinence aids and cotton products (+1.7%), Mark Medical (+12.4%) and Bormia (+30.0%) – both engaged in the marketing of specialist medical devices in the Balkan area; the three Business Units account for approximately 80% of the Group’s consolidated revenues.
“We are satisfied with the results achieved in the first six months of the year, we have given a great boost to the development of the concessions in the portfolio, in particular to the Cardiac Surgery, Cardiology and Radiology lines”, commented theAD Umberto Perillo.